Accordingly, a co-inhibition of TGF-β and PD-L1 (using their preclinical EMT6 model) reduced TGFβ signaling in stromal cells to facilitate T-cell penetration into the center of tumors, which induced anti-tumor immunity and tumor regression. Here, CD274 is linked to neoplasm.